Alifiya Kapasi1, Lei Yu2, Patricia A Boyle2, Lisa L Barnes2, David A Bennett2, Julie A Schneider2. 1. From the Rush Alzheimer's Disease Center (A.K., L.Y., P.A.B., L.L.B., D.A.B., J.A.S.), Department of Pathology (A.K., J.A.S.), Department of Neurological Sciences (L.Y., L.L.B., D.A.B., J.A.S.), and Department of Behavioral Sciences (P.A.B., L.L.B.), Rush University Medical Center, Chicago, IL. Alifiya_Kapasi@Rush.edu. 2. From the Rush Alzheimer's Disease Center (A.K., L.Y., P.A.B., L.L.B., D.A.B., J.A.S.), Department of Pathology (A.K., J.A.S.), Department of Neurological Sciences (L.Y., L.L.B., D.A.B., J.A.S.), and Department of Behavioral Sciences (P.A.B., L.L.B.), Rush University Medical Center, Chicago, IL.
Abstract
OBJECTIVE: To examine the impact of 3 pathologic groups, pure limbic-predominant age-related transactive response DNA-binding protein 43 encephalopathy (LATE) neuropathologic changes (NC), pure Alzheimer disease neuropathologic change (ADNC), and mixed ADNC with LATE-NC, on late-life cognitive decline. METHODS: Data came from 1,356 community-based older persons who completed detailed annual cognitive testing and systematic neuropathologic examination at autopsy to identify LATE-NC, ADNC, and other age-related pathologies. Persons were categorized into (0) a group without a pathologic diagnosis of LATE or ADNC (n = 378), (1) LATE-NC without ADNC (n = 91), (2) ADNC without LATE-NC (n = 535), and (3) mixed ADNC with LATE-NC (n = 352). We used mixed-effect models to examine the group associations with rate of decline in global cognition and 5 cognitive domains and then examined whether age modified associations. RESULTS: Compared to those without LATE-NC or ADNC, those with pure LATE-NC had a faster decline in global cognition (p = 0.025) and episodic memory (p = 0.002); however, compared to persons with pure ADNC, those with pure LATE-NC showed a slower decline. Those with mixed ADNC with LATE-NC showed the fastest decline compared to those with either pathology alone. Persons ≥90 years of age with mixed ADNC with LATE-NC had slower cognitive decline compared to those ≤89 years of age. CONCLUSION: Persons with pure LATE-NC follow a slower trajectory compared to those with pure ADNC. Those with mixed LATE/ADNC have a steeper decline than individuals with either pathology alone. In addition, age may modify the effect of pathology on cognitive decline. These findings have important implications for the development of biomarkers and prognosis for late-life cognitive decline. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that LATE-NC and Alzheimer disease pathologic changes are associated with different trajectories of late-life cognitive decline.
OBJECTIVE: To examine the impact of 3 pathologic groups, pure limbic-predominant age-related transactive response DNA-binding protein 43 encephalopathy (LATE) neuropathologic changes (NC), pure Alzheimer disease neuropathologic change (ADNC), and mixed ADNC with LATE-NC, on late-life cognitive decline. METHODS: Data came from 1,356 community-based older persons who completed detailed annual cognitive testing and systematic neuropathologic examination at autopsy to identify LATE-NC, ADNC, and other age-related pathologies. Persons were categorized into (0) a group without a pathologic diagnosis of LATE or ADNC (n = 378), (1) LATE-NC without ADNC (n = 91), (2) ADNC without LATE-NC (n = 535), and (3) mixed ADNC with LATE-NC (n = 352). We used mixed-effect models to examine the group associations with rate of decline in global cognition and 5 cognitive domains and then examined whether age modified associations. RESULTS: Compared to those without LATE-NC or ADNC, those with pure LATE-NC had a faster decline in global cognition (p = 0.025) and episodic memory (p = 0.002); however, compared to persons with pure ADNC, those with pure LATE-NC showed a slower decline. Those with mixed ADNC with LATE-NC showed the fastest decline compared to those with either pathology alone. Persons ≥90 years of age with mixed ADNC with LATE-NC had slower cognitive decline compared to those ≤89 years of age. CONCLUSION: Persons with pure LATE-NC follow a slower trajectory compared to those with pure ADNC. Those with mixed LATE/ADNC have a steeper decline than individuals with either pathology alone. In addition, age may modify the effect of pathology on cognitive decline. These findings have important implications for the development of biomarkers and prognosis for late-life cognitive decline. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that LATE-NC and Alzheimer disease pathologic changes are associated with different trajectories of late-life cognitive decline.
Authors: J A Schneider; R S Wilson; E J Cochran; J L Bienias; S E Arnold; D A Evans; D A Bennett Journal: Neurology Date: 2003-04-08 Impact factor: 9.910
Authors: Vanessa D Smith; Adam D Bachstetter; Eseosa Ighodaro; Kelly Roberts; Erin L Abner; David W Fardo; Peter T Nelson Journal: Brain Pathol Date: 2017-03-24 Impact factor: 6.508
Authors: John L Robinson; Edward B Lee; Sharon X Xie; Lior Rennert; EunRan Suh; Colin Bredenberg; Carrie Caswell; Vivianna M Van Deerlin; Ning Yan; Ahmed Yousef; Howard I Hurtig; Andrew Siderowf; Murray Grossman; Corey T McMillan; Bruce Miller; John E Duda; David J Irwin; David Wolk; Lauren Elman; Leo McCluskey; Alice Chen-Plotkin; Daniel Weintraub; Steven E Arnold; Johannes Brettschneider; Virginia M-Y Lee; John Q Trojanowski Journal: Brain Date: 2018-07-01 Impact factor: 13.501
Authors: Bryan D James; Robert S Wilson; Patricia A Boyle; John Q Trojanowski; David A Bennett; Julie A Schneider Journal: Brain Date: 2016-11-01 Impact factor: 13.501
Authors: Robert S Wilson; L L Barnes; C F Mendes de Leon; N T Aggarwal; J S Schneider; J Bach; J Pilat; L A Beckett; S E Arnold; D A Evans; D A Bennett Journal: Neurology Date: 2002-08-13 Impact factor: 9.910
Authors: Robert S Wilson; Ana W Capuano; David A Bennett; Julie A Schneider; Patricia A Boyle Journal: Neuropsychology Date: 2016-04-25 Impact factor: 3.295
Authors: David A Bennett; Aron S Buchman; Patricia A Boyle; Lisa L Barnes; Robert S Wilson; Julie A Schneider Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Willa D Brenowitz; Sarah E Monsell; Frederick A Schmitt; Walter A Kukull; Peter T Nelson Journal: J Alzheimers Dis Date: 2014 Impact factor: 4.472
Authors: Peter T Nelson; Dennis W Dickson; John Q Trojanowski; Clifford R Jack; Patricia A Boyle; Konstantinos Arfanakis; Rosa Rademakers; Irina Alafuzoff; Johannes Attems; Carol Brayne; Ian T S Coyle-Gilchrist; Helena C Chui; David W Fardo; Margaret E Flanagan; Glenda Halliday; Suvi R K Hokkanen; Sally Hunter; Gregory A Jicha; Yuriko Katsumata; Claudia H Kawas; C Dirk Keene; Gabor G Kovacs; Walter A Kukull; Allan I Levey; Nazanin Makkinejad; Thomas J Montine; Shigeo Murayama; Melissa E Murray; Sukriti Nag; Robert A Rissman; William W Seeley; Reisa A Sperling; Charles L White; Lei Yu; Julie A Schneider Journal: Brain Date: 2019-06-01 Impact factor: 15.255
Authors: Merilee A Teylan; Charles Mock; Kathryn Gauthreaux; Jessica E Culhane; Gregory Jicha; Yen-Chi Chen; Kwun C G Chan; Walter A Kukull; Peter T Nelson; Yuriko Katsumata Journal: J Neuropathol Exp Neurol Date: 2021-10-01 Impact factor: 3.685
Authors: Denis S Smirnov; David P Salmon; Douglas Galasko; Steven D Edland; Donald P Pizzo; Vanessa Goodwill; Annie Hiniker Journal: Ann Neurol Date: 2022-07-11 Impact factor: 11.274
Authors: Vijay K Ramanan; Timothy G Lesnick; Scott A Przybelski; Michael G Heckman; David S Knopman; Jonathan Graff-Radford; Val J Lowe; Mary M Machulda; Michelle M Mielke; Clifford R Jack; Ronald C Petersen; Owen A Ross; Prashanthi Vemuri Journal: Acta Neuropathol Commun Date: 2021-03-23 Impact factor: 7.578
Authors: Caitlin S Latimer; Jade G Stair; Joshua C Hincks; Heather N Currey; Thomas D Bird; C Dirk Keene; Brian C Kraemer; Nicole F Liachko Journal: Dis Model Mech Date: 2022-04-27 Impact factor: 5.732
Authors: Breton M Asken; Lawren VandeVrede; Julio C Rojas; Corrina Fonseca; Adam M Staffaroni; Fanny M Elahi; Cutter A Lindbergh; Alexandra C Apple; Michelle You; Sophia Weiner-Light; Nivetha Brathaban; Nicole Fernandes; Adam L Boxer; Bruce L Miller; Howie J Rosen; Joel H Kramer; Kaitlin B Casaletto Journal: J Int Neuropsychol Soc Date: 2021-06-22 Impact factor: 3.114